Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Leuk Res. 2013 May 10;37(8):974–979. doi: 10.1016/j.leukres.2013.04.018

Figure 4.

Figure 4

Inhibition of XIAP decreases proteasome activity in a caspase-dependent manner in HL-60 cells. HL-60 cells were pretreated for 1 hour with pan-caspase inhibitor z-VAD, electroporated with XIAP NSO/ASO, and then treated with bortezomib for 24 hours in the presence of z-VAD. The previously-seen reduction in 20S proteasome activity by ASO treatment was abolished, including its enhancement of the effect of bortezomib by the caspase inhibitor, but it had no effect on the inhibition of proteasome activity by bortezomib. Data are the result of 3 experiments. Bars indicate the standard error of the mean. Asterisks indicate significant (p < 0.05) differences from treatment with the NSO control plus DMSO.